Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 17/20 | 0.50 |
| ▸ | STS | P08842 | 7/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10172736 | 0.83 | CYP19A1 (0.50) | CYP19A1STSCA2HDAC1HDAC6 | |
| SCHEMBL305324 | 0.82 | CYP19A1 (0.73) | CYP19A1STSCA2 | |
| SCHEMBL10172807 | 0.79 | CYP19A1 (0.71) | CYP19A1STSCA2 | |
| SCHEMBL10172744 | 0.78 | CYP19A1 (0.44) | CYP19A1STSCA2 | |
| SCHEMBL12268248 | 0.78 | CYP19A1 (0.44) | CYP19A1STSCA2HDAC1HDAC6 | |
| SCHEMBL10172571 | 0.77 | CYP19A1 (0.50) | CYP19A1STSHDAC1HDAC6 | |
| SCHEMBL307287 | 0.77 | CYP19A1 (0.58) | CYP19A1STSHDAC1HDAC6 | |
| SCHEMBL10172826 | 0.75 | CYP19A1 (0.51) | CYP19A1STSCA2 | |
| SCHEMBL10172785 | 0.74 | CYP19A1 (0.51) | CYP19A1STSCA2 | |
| SCHEMBL10172835 | 0.74 | CYP19A1 (0.72) | CYP19A1STSCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093279-B2 | Compound | STERIX LIMITED (GB) | 2012-01-10 | — | — | US | disclosed |
| US-8022224-B2 | 1,2,4-triazol-1-yl bisphenyl derivatives for use in the treatment of endocrine-dependent tumors | STERIX LIMITED (GB) | 2011-09-20 | — | — | US | disclosed |
| US-20100173963-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20080319037-A1 | 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS | STERIX LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319037-A1 | 1,2,4-TRIAZOL-1-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMORS | CYP19A1, CYP21A2, CBR1 | CYP19A1 1/4885STS 26/4885CA2 502/4885 |
| US-20100173963-A1 | COMPOUND | CBR3, CBR1, OXSR1 | CYP19A1 605/4885STS 1844/4885CA2 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.